Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29871648 | 0.85 | GPR84 (0.87) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL22554662 | 0.85 | GPR84 (0.73) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL10566282 | 0.83 | HTR7 (0.63) | GPR84CSNK2A1NPC1HTR7HTR6 | |
| SCHEMBL2161423 | 0.83 | GPR84 (0.76) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL2161735 | 0.82 | GPR84 (0.70) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL3974212 | 0.81 | NPC1 (0.80) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL12844152 | 0.81 | GPR84 (0.68) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL8528962 | 0.81 | GPR84 (0.68) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL31571584 | 0.81 | GPR84 (0.68) | GPR84NPC1HTR7HTR6KMT2A | |
| SCHEMBL27142546 | 0.81 | GPR84 (0.68) | GPR84NPC1HTR7HTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| WO-2013026162-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-4795756-A | VASOCONSTRICTOR FOR MIGRAINE HEADACHE | GLAXO GROUP LIMITED (GB) | 1989-01-03 | — | — | US | disclosed |
| EP-0244085-A2 | 3-(2-Aminoethyl)indole derivatives | GLAXO GROUP LIMITED (GB) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | GPR84 2925/4885CSNK2A1 64/4885NPC1 4214/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | GPR84 2925/4885CSNK2A1 64/4885NPC1 4214/4885 |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HAVCR2, CD4, HAX1 | GPR84 1765/4885CSNK2A1 1968/4885NPC1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.